A group of 18 colorectal cancer patients experienced complete remission after taking the experimental drug dostarlimab for ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Tirzepatide is a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors that results in 12 to 21% weight loss in patients with obesity; however ...

MSD's powerhouse PD-1 inhibitor Keytruda (pembrolizumab ... which has been published in the New England Journal of Medicine. The drug has previously been cleared in the UK, Switzerland, and ...

In the phase 3 ALINA study published recently in the New England Journal of Medicine, adjuvant Alecensa ... MSD's $25 billion immunotherapy Keytruda (pembrolizumab) alongside chemotherapy before ...

Both the EC and FDA approvals draw on data from the DUO-E trial, published in the Journal of Clinical Oncology ... there is a significant need for new treatment options for pMMR disease in ...

Both the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) launched new initiatives ... a Promising Innovative Medicine (PIM) designation ...

“This presents a great opportunity for this medicine to make a meaningful impact on advanced urothelial cancer patients, who face an urgent need for new therapies.” Chemo-immunotherapy comes ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of ...

Our family fishes commercially in New England, where we grow or catch a substantial portion of our food. About 15 years ago, my children and I began capturing bushels of European green crabs for ...

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

1 Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 2 Department of Health Policy and Management, Yale School of Public Health ...